Skip to Content

James C. Yao, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1995 Baylor College of Medicine, Houston, TX, MD
1991 Rice University, Houston, TX, BA, Computer Science

Postgraduate Training

7/1998-6/2001 Clinical Fellowship, Medical Oncology, M. D. Anderson Cancer Center, Houston, TX, Robert A. Wolff

Board Certifications

1/2003 Board Certification in Medical Oncology (ABIM)
1/1999 Board Certification in Internal Medicine (ABIM)

Experience/Service

Administrative Appointments/Responsibilities

Deputy Department Chair, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 3/2007-present
Faculty Supervisor of Mid-Level Providers Program, M. D. Anderson Cancer Center Department of Gastrointestinal Medical Oncology, Houston, TX, 9/2003-present

Institutional Committee Activities

Member, Southwest Oncology Group (SWOG) Executive Committee, 9/2006-present

Professional Memberships

American Society of Clinical Oncology (ASCO)
Member, 1/2003-present
North American Neuroendocrine Tumor Society (NANETS)
Executive Committee, Research Coordinator, 1/2007-present
Southwest Oncology Group (SWOG)
Member, 1/2006-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Clark OH, Ajani JA, Benson AB 3rd, Berlin JD, Blaszkowsky LS, Byrd D, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kandeel F, Kessinger A, Kulke MH, Kunz P, Kvols L, Olson JA Jr, Ratliff TW, Salem R, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, Yao JC. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine Tumors. Jounal of the National Comprehensive Cancer Network 7(7):712, 7/2009. PMID: 19635226.
2. Yu G, Wang J, Chen Y, Wang X, Pan J, Li G, Jia Z, Li Q, Yao JC, Xie K. Overexpression of Phosphorylated Mammalian Target of Rapamycin Predicts Lymph Node Metastasis and Prognosis of Chinese Patients with Gastric Cancer. Clin Cancer Res 15(5):1078-0432, March 1, 1009, 2/2009. PMID: 19223493.
3. Badgwell B, Cormier JN, Xing Y, Yao J, Bose D, Krishnan S, Pisters P, Feig B, Mansfield P. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol 16(4):1074-1076, 1/2009. PMID: 18985270.
4. Scott LC, Yao JC, Benson AB 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Chemother Pharmacol 63(2):363-70, 12/2008. PMID: 18398613.
5. Truong CD, Li W, Feng W, Cagle P, Khoury T, Alrawi S, Xie K, Yao J, Tan D. Alpha-Methylacyl-CoA Racemase Expression is Upregulated in Gastric Adenocarcinoma: A Study of 249 Cases. Int J Clin Exp Pathol 1(6):518-523, 12/2008. PMCID: PMC480587.
6. Phan AT, Yao JC. Neuroendocrine tumors: novel approaches in the age of targeted therapy. Oncology 22(14):1617-23, 12/2008.
7. Wang L, Guan X, Zhang J, Jia Z, Wei D, Li Q, Yao J, Xie K. Targeted inhibition of Sp1-mediated transcription for antiangiogenic therapy of metastatic human gastric cancer in orthotopic nude mouse models. Int J Oncol 33(1):161-7, 12/2008. PMID: 18575762.
8. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess KR, Gupta S, Jacobs C, Mares J, Landgraf A, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. Journal of Clinical Oncology 26(26):4311-4318, 9/2008.
9. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdallas E, Fleming JB, Vauthey JN, Rashid A, Evans DB. One Hundred Years After Carcinoid: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology 26(18), 6/2008.
10. Hassan MM, Phan A, Li D, Dagohoy, CG, Leary C, Yao JC. Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiology Biomarkers Prev 17(4):959-65, 4/2008.
11. Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. Endocr Relat Cancer 15(1):257-66, 3/2008.
12. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316-23, 3/2008. e-Pub 3/2008.
13. Murthy R, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R, Yao JC. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol 19(1):145-51, 1/2008.

Abstracts
1. M. A. Mani, R. T. Shroff, C. Jacobs, R. A. Wolff, J. A. Ajani, J. C. Yao, A. T. Phan. A phase II study of irinotecan and cisplatin for metastatic or unresectable high grade neuroendocrine carcinoma. Journal of Clinical Oncology, 2008 ASCO Annual Meeting 26, 5/2008.

Book Chapters
1. Yao JC, Xie K. Development of Novel Therapeutic Agents for Neuroendocrine Tumors. In: A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Felsenstein CCCP, 370-377, 2008.
2. Yao JC, Gupta S, Vauthey JN, Evans DB. Management of Nonfunctional Islet Cell - Carcinomas of the Pancreas. In: Advanced Therapy in Surgical Oncology. Ed(s) Pollock RE, Curley SA, Ross MI, Perrier NE. BC Decker Inc. Lewiston, New York, 443-448, 2008. PMID: 978-1-55009-126-7.
3. Yao JC, Rindi G, Evans DB. Pancreatic Endocrine Tumors. In: CANCER Principles & Practice of Oncology, 8th Edition. DeVita, 2008.

Letters to the Editor
1. Matthew H. Kulke, Emily K. Bergsland, James C. Yao. Glycemic Control in Patients with Insulinoma Treated with Everolimus. New England Journal of Medicine 360(2):195-197, 1/2009.
2. Yao JC, Kvols LK. Octreotide LAR in Carcinoid: How to Dose? Pancreas 37(3):337-338, 10/2008.

Last updated: 10/22/2009